製品: ATOX1 Antibody
カタログ: DF13934
タンパク質の説明: Rabbit polyclonal antibody to ATOX1
アプリケーション: IHC IF/ICC
Cited expt.: IHC
反応性: Human, Mouse, Rat
分子量: 10kD; 7kD(Calculated).
ユニプロット: O00244

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
クローナリティ:
Polyclonal
特異性:
ATOX1 Antibody detects endogenous levels of total ATOX1.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

ATOX1; ATOX1_HUMAN; ATX1; ATX1 antioxidant protein 1 homolog (yeast); ATX1 antioxidant protein 1 homolog; Copper transport protein; Copper transport protein ATOX1; HAH1; Metal transport protein; Metal transport protein ATX1; MGC138453; MGC138455;

免疫原

免疫原:

A synthesized peptide derived from Human ATOX1.

Uniprot:
遺伝子(ID):
発現特異性:
O00244 ATOX1_HUMAN:

Ubiquitous.

タンパク質配列:
MPKHEFSVDMTCGGCAEAVSRVLNKLGGVKYDIDLPNKKVCIESEHSMDTLLATLKKTGKTVSYLGLE

研究背景

機能:

Binds and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense.

組織特異性:

Ubiquitous.

タンパク質ファミリー:

Belongs to the ATX1 family.

研究領域

· Organismal Systems > Digestive system > Mineral absorption.

参考文献

1). Curcumin suppresses copper accumulation in non-small cell lung cancer by binding ATOX1. BMC pharmacology & toxicology, 2024 (PubMed: 39169392) [IF=2.9]

Application: WB    Species: human    Sample: A549 and H1299 cells

Fig. 1 Effects of curcumin on ATOX1-associated copper chaperones in A549 and H1299 cells. (A) The binding activity between curcumin and ATOX1 protein was analyzed using molecular docking. (B) Cell viability was measured by CCK-8. (C) Levels of ATOX1, ATP7A, and COX17 proteins were measured by western blotting. The levels of proteins were normalized by β-actin. The full-length blots were shown in Supplementary Fig. 1 and Fig. 2. (D) The semi-quantitative analysis of the blots was analyzed by ImageJ software. (E) Effects of DC-AC50 treatment on cell viability. Three parallel experiments were performed in cells. NS no significance. *p 

Application: IHC    Species: human    Sample: A549 cells

Fig. 5 Curcumin inhibited tumor growth by suppressing ATOX1. The animal model was established by injection of A549 cells. After 6 days of injection, the mice were injected with 20 mg/kg/d DC-AC50 or 40 mg/kg/d curcumin by intraperitoneal injection for 21 days. (A) Tumor volume was measured every week. (B) Tumor weight was obtained. Expressions of ATOX1 in tumor tissues were measured by immunohistochemistry (C) and western blotting (D). Black arrows: ATOX1 expression. The full-length blots were presented in Supplementary Fig. 7. Six animals in each group. *p 

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.